Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis (formerly Sanofi-Synthelabo) covers the period ending December 8, 2004. The report details the progress of a mandatory tender offer for shares in Hoechst Aktiengesellschaft (Hoechst AG). The filing serves to disclose the cumulative number of shares accepted into the offer as of specific cutoff times in early December 2004.
Key Financial Metrics
The filing text does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the volume of shares tendered in the mandatory offer for Hoechst AG.
- Shares Accepted (as of Dec 3, 2004): 248,933 shares (0.04% of share capital and voting rights).
- Shares Accepted (as of Dec 6, 2004): 251,603 shares (0.04% of share capital and voting rights).
- Shares Accepted (as of Dec 7, 2004): 259,035 shares (0.05% of share capital and voting rights).
Material Changes
The filing reports incremental increases in the number of Hoechst AG shares tendered to Sanofi-Aventis over a four-day period. Between December 3 and December 7, 2004, the total number of accepted shares increased by 10,102, raising the ownership stake from 0.04% to 0.05% of Hoechst's share capital and voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook regarding future performance. It does not explicitly list risks or contingencies beyond the ongoing nature of the mandatory offer. The document is a procedural update on the tender offer status.
Key Facts for Investor Verification
- Verify the total number of shares outstanding for Hoechst AG to confirm the percentage calculations (0.04% to 0.05%) provided in the notices.
- Confirm the current status of the mandatory offer, as this filing only covers the period up to December 7, 2004.
- Review the full text of Exhibits 99.1, 99.2, and 99.2 for any additional terms or conditions of the offer not summarized in the Form 6-K body.
- Note that this filing does not contain Sanofi-Aventis's own financial results for the period.